Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting
February 04, 2016 10:22 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) will present data from a human factors study with its G-PenTM glucagon auto-injector during the 9th International...
Xeris Pharmaceuticals Announces $41 Million Series C Financing
January 07, 2016 10:24 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance a Stable, Non-Aqueous Diazepam, Subcutaneous Injection for Treatment of Acute Repetitive Seizures in Patients with Epilepsy
October 01, 2015 10:15 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Oct. 01, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments, was...
Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions
June 21, 2013 10:00 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is
presenting at the American Diabetes Association 73nd Scientific
Sessions in Chicago, IL...
Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas
April 17, 2013 11:39 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based,
pharmaceutical company developing patient-friendly injectable
treatments for diabetes and other...
Xeris Pharmaceuticals Closed 2012 with $6M In Additional Funding
February 11, 2013 09:42 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging
pharmaceutical company developing patient-friendly injectable
treatments for diabetes,...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Bi-Hormonal Artificial Pancreas
July 31, 2012 10:41 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, July 31, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging
biopharmaceutical company developing patient-friendly injectable
treatments for diabetes...